A cross-talk between p16High senescence and cellular reprogramming
Clinical Science · 10.06.2026 · 140 (6) · 1137-1147
DOI: 10.1042/cs20260240 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Science, online erschienen am 29.05.2026. Verfasst von Alexander Emelyanov und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Research on Cancer and Aging of Nice (IRCAN), Université Côte d'Azur, INSERM, CNRS, Nice, France. Hauptthemen laut MEDLINE: Cellular Senescence, Cellular Reprogramming, Cyclin-Dependent Kinase Inhibitor p16. Die Arbeit nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche (ANR).
Abstract (Originalsprache)
Cellular senescence and OSKM (Oct4, Sox2, Klf4, and Myc)-mediated reprogramming represent interconnected biological programs that both play important roles in regulating cellular plasticity. Recent studies have highlighted the role of p16-driven senescence in establishing a stable barrier to reprogramming by limiting epigenetic flexibility. Mechanistically, p16High senescent fibroblasts enforce this barrier through stress-induced and AP-1-driven epigenetic remodeling and NNMT-mediated metabolic SAM depletion, which restricts methylation-dependent chromatin remodeling in both p16High and neighboring p16Low cells via a paracrine mechanism. Conversely, clearance of p16High cells restores SAM levels and enhances cellular plasticity in neighboring cells, enabling the acquisition of totipotent-like states during reprogramming. Within p16High cells themselves, reprogramming can reverse some features of senescence, restoring more youthful cellular states under controlled conditions. Importantly, p16High cells remain highly resistant to full reprogramming, minimizing the risk of teratoma and tumor formation in vivo and making them promising target for rejuvenation strategies based on partial reprogramming. In this review, we examine the molecular interplay between p16High senescence and reprogramming, highlighting their dual roles as both barriers to and facilitators of cell fate transitions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Research on Cancer and Aging of Nice (IRCAN), Université Côte d'Azur, INSERM, CNRS, Nice, France.
ORCID-Profile: Dmitry V Bulavin
Förderung
- Agence Nationale de la Recherche (ANR)
Zitieren
APA
Emelyanov, A., & Bulavin, D. V. (2026). A cross-talk between p16High senescence and cellular reprogramming. Clinical Science, 140(6), 1137-1147. https://doi.org/10.1042/cs20260240
Vancouver
Emelyanov A, Bulavin DV. A cross-talk between p16High senescence and cellular reprogramming. Clinical Science. 2026;140(6):1137-1147. doi:10.1042/cs20260240
BibTeX
@article{Emelyanov2026,
author = {Emelyanov, Alexander and Bulavin, Dmitry V},
title = {A cross-talk between p16High senescence and cellular reprogramming},
journal = {Clinical Science},
year = {2026},
volume = {140},
number = {6},
pages = {1137--1147},
doi = {10.1042/cs20260240}
}
EUVIMED